Summary This study is a case-control study looking to identify factors associated with frequent use of hospital services (emergency care and admissions) in COPD patients. Data from 64 patients with moderate-severe COPD (FEV 1 /FVCp70, FEV 1 p50%) were prospectively collected, 32 cases with high consumption of health resources (COPD-HC) and 32 controls. COPD-HC was defined as a patient diagnosed of COPD requiring during one year: (1) two or more hospitalizations; (2) three or more emergency visits; or (3) one admission and two emergency visits. Patients with COPD and a similar age, FEV 1 and PaO 2 who required no hospital care during the study year (1998) were randomly selected as controls. Demographic, clinical and socioeconomic data were collected from each subject, and evaluations were made of anxiety, health-related quality of life [measured with the St. George's Respiratory Questionnaire (SGRQ)], nutritional parameters, and different therapeutic aspects. Forced spirometry, resting arterial blood gases, maximal respiratory muscle pressures and a 6-min walking test were measured in all cases. After applying a logistic regression model, the variables that finally proved to be independent predictors of frequent use of hospital services were: treatment with salmeterol, the presence of cardiac arrhythmias, and increased SGRQ scores. The administration of inhaled salmeterol multiplied the risk of having COPD-HC criteria by 27.4 (95%CI: 2.4-308.1), while the presence of arrhythmias multiplied the probability of meeting high consumption criteria by 24.3 (95%CI: 1.7-340.1). For each point of worsened quality of life, the risk of hospital care increased 1.06-fold (95%CI: 1.01-1.10). Although a severity bias related to the presence of long-acting b 2 -agonists in the final regression equation cannot be ruled out, the variables associated in our sample to an increased utilization of hospital services are the regular use of inhaled salmeterol, the presence of cardiac arrhythmias, and an impaired health-related quality of life. The use of specific strategies aimed at modulating these aspects could, at least in theory, reduce the number of exacerbations requiring hospital care, with the resultant individual and collective benefits derived.
Introduction
Chronic obstructive pulmonary disease (COPD) has become one of the main causes of morbidity and mortality worldwide. In Spain, the estimated prevalence of the disease among the adult population aged 40-69 years is 9.1%, 1 and COPD is the fourth leading cause of death, 2 surpassed only by cancer and cardiac and cerebrovascular diseases. According to estimates of the National Health Heart, Lung and Blood Institute, the annual cost of COPD in the United States was 23.9 billion US dollars in 1993, with an average expenditure per patient and year of 1522 US dollars, almost three times the cost per capita of asthma. 3 In Spain, the cost of medical care associated with COPD during 1998 was estimated to be a little over 1.21 billion Euros. 4 Among the direct costs, the category with the greatest impact both in Spain and the United States was hospital expenses, which according to American studies could exceed 72% of the total direct costs of the disease. 5 These same sources point to the existence of a group of patients with high consumption of health resources (COPD-HC); while these patients account for only 10% of all COPD cases, they would account for 73% of the total expenditure. 5 In a previous study we found that 60.8% of hospital emergencies and 57.1% of all hospitalizations attributable to exacerbation of COPD correspond to this target population. 6 This subgroup of patients generally showed a higher severity profile, with lower forced expiratory volume in one second (FEV 1 ) values, increased hypoxemia and older age. However, seriously ill patients are often seen who hardly ever visit the hospital. This fact suggests a working hypothesis whereby in addition to being conditioned by the severity of the disease itself, the need for hospital care is very likely to be also modulated by other factors not currently identified. The purpose of this study was to attempt and identify these other factors predicting hospital care in the target population of COPD patients with high consumption of health resources.
Material and methods

Patient selection
A case-control study was conducted in 64 patients diagnosed of COPD. The inclusion criteria were a history of smoking (420 packs/year), and a FEV 1 p50% the predicted value, with a FEV 1 /FVC ratiop70%. The patients were selected from a larger Spanish study designed to establish the hospital care impact of COPD. 6 First, we identified patients (cases and controls) and then we prospectively did the evaluations. The cases consisted of all patients who met the criteria for COPD-HC in the year before the start of the study (1998) . A patient was considered to meet COPD-HC criteria when any of the following conditions had occurred during that year: (a) two or more hospital admissions for COPD decompensation; (b) three or more emergency visits for the same reason nor requiring hospital admission; or (c) one admission and two emergency visits for COPD exacerbation. Exacerbation of COPD was defined as any increase in respiratory symptoms compared to the baseline condition of the patient that required a change in standard medication and made hospital care necessary. The control group consisted of patients who required no hospital care during 1998 and were similar to the corresponding case in terms of age, resting arterial oxygen pressure (PaO 2 ) and FEV 1 . One control was randomly selected for each case.
Data collection
Demographic data were recorded for each patient, including distance from the hospital (in kilometers) and socioeconomic status based on a three-level index adapted from Prescott et al. 7 : (a) low socioeconomic index, comprising patients with limited education (less than 10 years) and a low income (o450 Euros/month); (b) intermediate socioeconomic index (i.e., patients belonging neither to level (a) nor (c); and (c) high socioeconomic index, comprising patients with greater education (414 years) and a medium to high income (4900 Euros/month). The clinical variables recorded consisted of respiratory symptoms, the existence of comorbidity, and the presence of complications related to COPD. The respiratory symptoms recorded were those reported by the patients at the time of the interview. All patients were asked about the estimated duration of the disease (in years). Dyspnea was evaluated by Mahler's baseline dyspnea index (BDI). 8 Comorbidity was recorded as concomitant cardiac, neurological or gastrointestinal diseases, chronic renal failure, neoplastic conditions or other respiratory diseases. The presence of cardiac arrhythmias was not regarded as cardiac comorbidity but rather as a possible complication of COPD. Complications related to COPD were taken to be the presence of respiratory failure, chronic cor pulmonale, cardiac rhythm disorders, or primary bronchogenic carcinoma. Pulmonary hypertension was not analyzed.
The Spanish version of St. George's Respiratory Questionnaire (SGRQ) was used to analyze healthrelated quality of life (HRQoL). 9 This questionnaire consists of 50 items (covering 76 levels), in turn divided into three subscales of symptoms, activity and impact. The score ranges from 0 to 100, where 0 indicates no HRQoL impairment. Anxiety was assessed by the State-Trait Anxiety Inventory (STAI-S/T), 10 a self-administered questionnaire that includes two independent scales which evaluate different aspects of anxiety: as state (S) and as trait (T). The former refers to how the individual feels at that time, while the latter refers to how the patient feels in general. On each scale, the patient is required to answer 20 questions which are scored from 0 (''none'' on the STAI-S; ''almost never'' on the STAI-T) to 3 (''much'' on the STAI-S; ''almost always'' on the STAI-T); thus, the final score can range from a minimum of 0 to a maximum of 60 points. An individual is considered to suffer from an anxiety disorder when the STAI-T score exceeds 38 points. The following anthropometric parameters were measured to establish the nutritional status of the patients: weight, height, tricipital skin folds and the mid-arm muscle circumference of the non-dominant arm. Based on these measurements, the following indices and values were calculated: body mass index (BMI), muscle perimeter of the arm, mid-arm muscle area (MAMA), and mid-arm fat area (MAFA). Skin folds were measured with a Holtain lipocalibrator using the standard method in nutritional studies. 11 Folds were always measured by the same examiner with the patient under relaxed conditions. The final measure was the average of three consecutive measurements of each fold. All patients were subjected to blood tests under baseline conditions, with measurement of albumin (mg/dl) and transferrin (mg/dl) levels.
Forced spirometry (Autospiro AS-600 spirometer, Minato Medical Science, S.A.) was used to measure FEV 1 and forced vital capacity (FVC) according to the procedure established by the Sociedad Espa* nola de Neumolog! ıa y Cirug! ıa Tor ! acica (SEPAR).
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The results of FEV 1 and FVC are expressed as percentages of the adult reference values. 13 Arterial blood samples were collected and analyzed according to the method recommended by the SEPAR. 14 Both spirometry and arterial blood gases were measured in a stable phase, i.e. more than two months after an exacerbation. The classical procedure described by Black and Hyatt was used to measure the maximal respiratory muscle pressures. 15 The theoretical values used are those reported by Morales et al. 16 The 6-min walking test (6MWT) was performed along a 32-m corridor of the hospital, according to the protocol established by Butland et al. 17 During the test, arterial oxygen saturation (SaO 2 ) was continuously measured using a pulsioxymeter (Pulsox-5, Minolta. AVL Medical Instruments AG). The test was repeated twice, both on the same day and at least one hour apart. The best result was used for subsequent data analysis. As reference equations we used those reported by Enright and Sherrill. 18 The treatment received by each patient at the time of the interview was recorded. None of the patients had previously undergone lung reduction surgery or non-invasive mechanical ventilation at home.
Statistical analysis
The quantitative data are given as the mean7 standard deviation (SD). A w 2 test was used to compare proportions. The Student-Fisher t-test for non-paired samples was used to compare means, after checking the assumption of normality by the Kolmogorov-Smirnov test. The quantitative variables not following a normal distribution were compared using the Mann-Whitney's U-test. The assumed alpha error was 0.05. For all variables showing statistically significant differences between the study groups in the univariate analysis, a Pearson correlation ðrÞ was applied for quantitative data, and a Spearman ordinal correlation ðr s Þ for qualitative data, in order to avoid collinearity between variables. Among variables mutually correlated with r or r s X0:6; we selected for subsequent multivariate analysis those whose significance level was greatest in the previous univariate study. A multivariate analysis applying logistic regression was performed to all the data that passed the above screening process. The statistical software used for data processing was SPSS version 9 for Windows.
Results
The mean age of the 64 patients was 7278 years; they all were males. 
Univariate analysis
There were no significant differences between groups in smoking habit, distance between the city of origin and the hospital, or the modified socioeconomic index (Table 2 ). Both the general BDI scale and the subscales of functional impairment, task magnitude and effort magnitude were significantly superior in patients with COPD-HC ( Table 2) . Comorbidity was similar in both groups (Table 3) . Fig. 1 summarizes the complications related to COPD in each group. Significant differences were only found between the groups in the presence of cardiovascular arrhythmias, which were more common in the patients with COPD-HC. Only one control (3.3%) had chronic atrial fibrillation, as compared to 12 cases (37.5%). The odds ratio (OR) was 18.6 (95%CI-OR: 2.2-154.3). No differences were found for the rest of variables, though statistical significance was almost reached in the presence of chronic cor pulmonale, which was somewhat more frequent among the cases ðP ¼ 0:08Þ: HRQoL, as measured by the SGRQ, was significantly worse among the cases with COPD-HC, both in the overall scale and in the symptoms, activity and impact subscales (Fig. 2) . The mean scores obtained with the STAI-S and STAI-T questionnaires were within the normal range [15.9 (10.5) and 22.2 (10.6), respectively]. No significant differences were seen between the two groups for anxietystate or anxiety-trait. Quantitative data are given as mean7standard deviation (SD). Qualitative variables are given as the number of cases and their proportion in brackets. BDI: baseline dyspnea index. The data are given as the number of cases and their proportion in brackets.
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n Some patients had several diseases simultaneously. w one patient with arterial hypertension also had concomitant isquemic heart disease. z SAHS: Sleep apnea-hypoapnea syndrome. Table 4 shows the anthropometric and biological parameters used in the nutritional analysis. None of the functional respiratory parameters analyzed showed significant differences between the groups (Table 5 ). Significant differences were only seen during the 6MWT in the percentage time with SaO 2 values below 80%, 70% and 60%. The time with SaO 2 o90% during the walking test was similar in both groups. 
Logistic regression
The variables shown to be independent predictors of hospital care consumption among patients with severe COPD were the presence of arrhythmias, a poorer HRQoL, and treatment with inhaled salmeterol (Table 7) .
Discussion
Our results suggest that in patients with COPD of similar severity, the factors most contributing to repeated use of hospital services (both visits to emergency departments and hospital admissions) are the regular use of inhaled salmeterol, the presence of cardiac arrhythmias and the existence ARTICLE IN PRESS of an impaired HRQoL. As regards the latter, and although its three components (impact, activity and symptoms) are poorer in patients with COPD-HC, dyspnea, as main symptom, is the factor that most conditions the need for repeated hospital care.
Inhaled salmeterol as a predictor of hospital care
Various series have shown that salmeterol is a drug useful and safe in the treatment of COPD. 19, 20 For this reason, and because our study was not specifically designed to evaluate the efficacy and safety of this substance, its presence in the final regression equation is an unexpected finding. In our opinion, the possible explanations of this observation are varied and not necessarily mutually exclusive. First, a potential bias (perhaps in severity) should be considered. Second, inadequate patient response to the drug could be involved. Third, it should be evaluated whether salmeterol is able to produce significant side effects that could explain the observed phenomenon. Finally, the possibility of interactions should be assessed.
Lanes et al., 21 in a study of more than 61,000 asthmatic patients, of which 2708 were using salmeterol, noted that the latter showed significantly higher hospitalization percentages and stays in intensive care units (ICU) than the group treated with theophyllines. However, after adjusting for severity, salmeterol was not seen to cause an increased risk of hospitalization, emergency visits or stays at ICUs. In this same line, Williams et al., 22 in a case-control study conducted in the United Kingdom, showed that patients using salmeterol were not at a greater risk of life-threatening asthma attacks. In our series we have attempted to eliminate such severity bias by using controls of similar age, FEV 1 and PaO 2 . This approach makes it unlikely that severity is the main reason for the differences in salmeterol use seen between the two groups. However, it does not allow to rule out a bias resulting from hospitalization itself, since prior hospital admissions could, at least theoretically, have conditioned the subsequent use of this longacting bronchodilator (due to a false severity bias). All patients treated with salmeterol were regularly using this drug before January 1998, the year in which all hospital care reported in this study was provided, nevertheless we have no data about the time when such treatment was started, whether it was prescribed as the result of a previous admission, or whether a temporal relationship existed between salmeterol administration and the need for hospital care. The absence of these data and the study design do not allow us to establish that specific therapies may cause specific long-term consequences. However, this possibility cannot be ruled out. Different pharmacoepidemiological studies suggest a strong association between the increasing use of regularly administered b 2 -agonists and a loss of sensitivity and/or a decrease in the number of b 2 -adrenergic receptors, with the resulting loss of bronchodilator effect. [23] [24] [25] This phenomenon could lead to an inadequate patient response to treatment and thus possibly explain our findings. Nevertheless, this observation is controversial, as other series report no sensitivity loss after treatment with salmeterol 26, 27 or formoterol. 27 This discrepancy in results could be due to multiple factors, including the different methodological designs used and the possible differences in the populations studied. The existence of various polymorphisms in b 2 -adrenergic receptors that can cause different signals and/or different regulation on chronic exposure to b 2 -agonists has recently been reported. 28 It has been suggested that such polymorphisms could be associated to asthma of different severity, and a relation to the degree of desensitization to the bronchodilating effect of bagonists has even been reported. 29 This attractive hypothesis seen in the context of our study could account for the greater use of hospital care seen among patients using long-acting b-agonists administered on a regular basis. However, b 2 -receptor polymorphism does not seem to explain the differences seen between salmeterol and formoterol in our series.
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The third aspect to be considered is the existence of drug-related side effects. Various clinical studies have shown that salmeterol has a good safety profile, with minor side effects that in most cases are similar to those caused by placebo. 19, 20 These studies have usually been conducted in outpatients who were generally well controlled and with no associated comorbidity. However, the biological effects could be different under conditions closer to the real situation, where patients often have concomitant diseases or where severe exacerbations occur requiring simultaneous administration of other drugs. Cazzola et al., 30 in a series of patients with COPD, pre-existing heart arrhythmias and hypoxemia, suggested that long-acting b 2 -adrenergic drugs may have adverse effects upon the myocardium, though at the standard doses of 50 mg of salbutamol or 12 and 24 mg of formoterol they seem to have a good safety margin. The results of the Italian group not only provide relevant information about the possible undesirable effect of salmeterol in our series, but also allow us to establish an association with the presence of heart arrhythmias, the second variable seen to be independently associated with the repeated use of hospital services. The profile of patients included in our study, with advanced disease, marked hypoxemia and frequent comorbidity, could explain why long-acting b 2 -agonists would be capable of causing undesirable cardiac effects even when no such effects occur in less advanced disease. A discrepancy with this notion is raised by the use of formoterol. This drug not only showed no significant association to the existence of cardiovascular arrhythmias, but was also more frequently used in the patients selected as controls. The clinical efficacy and duration of action of formoterol and salmeterol seem to be very similar. 31 Nevertheless, despite these similarities, there are some interesting differences between the two drugs: (1) the onset of action of salmeterol is slower than that of formoterol, 32 and (2) salmeterol behaves as a partial agonist, and formoterol as an almost complete agonist, in the smooth muscle of the airways. 33 According to the basic principles of agonist/antagonist interaction, a partial agonist must occupy more receptors than a complete agonist to induce the same effect, and also behaves as a functional antagonist in the presence of a highly effective agonist, since it activates the same receptor. Molimard et al., 33 in a recent study in human bronchial tissue, showed that in the presence of a contracted bronchus, salmeterol behaves like a functional antagonist of the most commonly used total agonists, such as isoprenaline, fenoterol, terbutaline, and particularly salbutamol. Formeterol showed no such antagonistic effect, though the maximum relaxation induced by salbutamol was reduced in the presence of formoterol pretreatment. If these results are confirmed in vivo, they could explain why in severe bronchial obstruction the response to rescue medication is not as satisfactory in patients pretreated with salmeterol as in patients regularly receiving formoterol.
Finally, the fourth aspect requiring consideration is the existence of interactions. Theophyllines cause severe tachycardia and arrhythmias even at serum levels considered to be within the therapeutic range. 34 This effect appears to be enhanced in the presence of salbutamol. 35 Based on this, we could perhaps expect an enhancement of the arrhythmogenic effect in patients who combine long-acting bronchodilators and theophyllines. However, to our knowledge no study has reported this phenomenon to date. We found no differences in theophylline use between the two groups studied, and no differences either in the combined use of both drugs.
Cardiac arrhythmias as a predictor of hospital care
Rhythm disorders, both supraventricular and ventricular, are common in patients with COPD, and their occurrence is included among the causes of exacerbation. This fact could account for the increased presence of arrhythmias in patients with frequent exacerbations. However, it does little to explain the reason for these arrhythmias in this special patient subgroup. The presence of preexisting coronary disease, hypertension, changes in arterial blood gases or the use of theophyllines and b 2 -agonists have been previously reported as potential arrhythmogenic factors in COPD. 36 The possible arrhythmogenic effect of salmeterol or theophyllines in our patients has been discussed before. Of the rest of causes, the coexistence of coronary disease could account for some of the rhythm disorders seen, but not all of them. Three (25%) of the 12 cases with heart arrhythmias had a history of ischemic heart disease. By contrast, none of the controls had documented ischemic heart disease. Arterial hypertension was similar in both groups. Hypercapnia does not seem to be a discriminating cause, since PaCO 2 was even higher among the controls. The degree of resting hypoxemia was likewise similar in both groups. However, during the 6-min walking test, patients with COPD-HC showed deeper desaturations. The clinical significance of this recurrent hypoxemia is not clear. Smith et al. 37 have recently studied the effect of exercise-induced hypoxemia upon myocardial repolarization in patients with severe COPD by measuring the dynamic effects of hypoxemia upon QTc dispersion. This electrocardiographic parameter represents regional differences in cardiac repolarization and is used as a non-invasive predictor of ventricular arrhythmias and sudden death. Under rest conditions, QTc dispersion has been correlated to ventricular extrasystoles in patients with COPD. 38 However, in the series reported by Smith et al., 37 the authors found no evidence that exercise-induced hypoxemia increases QTc dispersion. While such exercise-induced hypoxemia does not appear to be related to arrhythmias, more prolonged hypoxemia occurring during sleep does appear to be related. Flick and Block, 39 in a classical study, showed that these cardiac events occur very often at night in patients with COPD, suggesting arterial desaturation to be responsible. We did not perform nocturnal oximetry in our patients, and cannot therefore rule out the possibility that this hypothetical nocturnal hypoxemia was the cause of the greater number of arrhythmias seen.
We have classified rhythm disturbances as possible complications of COPD because they are sometimes a consequence of the disease itself (hypoxemia) or of its treatment (theophyllines, b 2 -adrenergic agents). However, arrhythmias may also result from comorbidity. If we had considered arrhythmias as cardiovascular comorbidity, significant differences would very likely have been found between the two groups, since the ''cases'' usually showed a greater comorbidity than the controls. Miratvilles et al., 40 in a study on outpatients with less severe disease, noted that comorbidity was an independent risk factor for hospitalization.
Health-related quality of life (HRQoL) as a predictor of hospital care
Various authors have previously related a worsening of HRQoL to an increased frequency of exacerbations, 41 admissions 42 and even hospital readmissions. 43 All these studies, including our own, demonstrate this association, but the design of these studies does not allow for a conclusion as to whether an impaired quality of life contributes as a cause to exacerbations in such patients or is a consequence of exacerbations. Osman et al., 43 in a retrospective study, found that an impaired HRQoL during the first hospital admission was significantly associated with the possibility of readmission. By contrast, Seemungal et al., 41 in a study on 70 patients with moderate to severe COPD, found that exacerbations caused a significant effect on health condition. Regardless of whether it is a cause or consequence, the association of HRQoL and COPD exacerbation is highly consistent, and the quality of life questionnaire could therefore be used as a good indicator to stratify patients by risk of exacerbation, hospitalization or readmission.
In the study by Osman et al., 43 although the three subscales showed differences between the patients, the impact subscale showed the greatest differences in the cases requiring readmission. As in the above study, a significantly higher score was found in our series for the three subscales in patients with COPD-HC, showing that the three components contribute to predict the need for hospitalization. However, the symptoms subscale showed the greatest differences between the two study groups. This subscale showed a strong correlation to the basal dyspnea index (BDI), suggesting dyspnea to be a symptom that greatly contributes to increased use of hospital services by patients with COPD-HC.
In COPD, the main mechanisms described for dyspnea are the sensation of muscular effort, hypoxemia, hypercapnia, dynamic compression of the airways, and in cases with pulmonary hypertension or vascular involvement, stimulation of pressure receptors located in the C fibers of the vascular endothelium. 44 In our study, hypoxemia was similar in both groups, and PaCO 2 was even higher in the control group. No differences were seen either in the degree of bronchial obstruction, and the increased dyspnea seen in patients with COPD-HC could therefore result from an increased sensation of muscular effort (related to a possible myopathy or due to hyperinflation itself) or be caused by a certain vascular involvement. We did not study pulmonary hypertension, and are therefore unable to rule out this possibility. However, Kessler et al., 45 in a series of 64 patients with severe COPD, found pulmonary artery pressure was the best predictor for hospitalization. In this study, increased PaCO 2 values were also shown to be an independent risk factor for hospitalization. Unlike the French study, we noted a PaCO 2 increase in the control group. Our patients were matched for PaO 2 and FEV 1 , and this may have contributed to this discrepancy in the results. For a similar degree of bronchial obstruction, the increased hypercapnia seen in the control group could be related to obesity. In our series, BMI was comparatively higher in the control group (2875 vs. 2673 kg/m 2 ), but not significantly. Overweight appears to be associated with a lesser need for hospitalization. In the study by Kessler et al., 45 84% of patients with BMI426 kg/m 2 were free of hospital admissions at 1 year.
As to the possible contribution of muscle weakness, Decramer et al., 46 found quadriceps strength to be associated with a greater number of hospital admissions. Weakness of the ventilatory muscles was also greater among the patients with more hospital admissions, although this parameter did not reach statistical significance. The authors related muscle weakness to the increased use of oral corticoids. In our series, no differences were seen between the two groups in respiratory muscle strength or in the 6-min walking test, which has been related to quadriceps strength by some authors. 47 Likewise, we observed no increased use of maintenance oral corticoids in patients with COPD-HC. However, some malnutrition markers were found in these subjects. Malnutrition may be a cause of myopathy in COPD, and this possibility cannot therefore be entirely ruled out. Finally, mention should be made of the possible role of hyperinflation as a cause of dyspnea in our patients. Dynamic hyperinflation occurring during exercise has been shown to be one of the main determinants of dyspnea and exercise tolerance in COPD. 48 However, to our knowledge no study has analyzed this variable as a predictor for hospitalization. Inspiratory capacity (IC) provides indirect measures of hyperinflation both at rest and during exercise. 49 We found no differences between the two groups in resting IC, though this test was not performed during exercise; thus, the possibility of an increased dynamic hyperinflation in patients with COPD-HC cannot be ruled out.
In conclusion, among patients with COPD of similar severity, the main predictors of hospital care seen in our series were treatment with inhaled salmeterol, the presence of cardiac arrhythmias, and an impaired HRQoL. We think that strategies intended to correct and modulate these aspects may afford a substantial reduction in hospital care in a target population of patients with a high consumption of health resources. This approach and multidisciplinary care for this patient subgroup is most likely to reduce not only hospitalization costs and emergency care requirements, but also their consequences in terms of morbidity, mortality and health-related quality of life. The existence of a severity bias regarding the possible adverse effect of salmeterol cannot be definitively ruled out. We therefore consider it necessary to conduct new studies, with a larger number of patients, to investigate the possible negative effect of long acting b-agonists (especially salmeterol) on hospitalization rate.
